CytomX - ein bahnbrechender Ansatz in der Tumortherapie (Seite 56)
eröffnet am 01.07.16 16:03:16 von
neuester Beitrag 01.05.24 17:27:40 von
neuester Beitrag 01.05.24 17:27:40 von
Beiträge: 1.462
ID: 1.234.534
ID: 1.234.534
Aufrufe heute: 1
Gesamt: 164.371
Gesamt: 164.371
Aktive User: 0
ISIN: US23284F1057 · WKN: A14158 · Symbol: CTMX
1,8600
USD
-3,63 %
-0,0700 USD
Letzter Kurs 21.05.24 NYSE
Neuigkeiten
16.05.24 · globenewswire  |
08.05.24 · globenewswire |
07.05.24 · globenewswire |
02.05.24 · wO Chartvergleich |
02.05.24 · Sharedeals |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,3500 | +54,80 | |
| 1,2200 | +32,36 | |
| 2,9100 | +30,49 | |
| 5,2400 | +21,86 | |
| 1,0200 | +20,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0600 | -14,88 | |
| 2,9000 | -16,91 | |
| 2,2001 | -20,57 | |
| 0,8401 | -23,63 | |
| 0,7601 | -23,98 |
Beitrag zu dieser Diskussion schreiben
Feedback
wenn dough bei Twitter schon schreibt: Complicated stock imho
Es gab nach einigen Monaten ein Update bei der CX-2009 Studie. Insgesamt sind es jetzt 28 Studienzentren, alle im Status rekrutierend. Mal schauen, wo die ersten Ergebnisse präsentiert werden. Auf älteren Folien von 2017 wurde noch ESMO18 genannt. auf neueren findet sich nur noch 2 Hälfte 2018.
Hoffe, dass auser JOSCHKA noch andere Experten sind, die den Stand der Entwicklung und DAten kommentieren und diskutieren
Im Oktober kommen die vollen Daten zu X-072 (" Follow-up data from Part A and Part B of the PROCLAIM-072 trial is expected to be presented in October at the Annual Meeting of the European Society of Medical Oncology in Munich, Germany.")
Im Oktober kommen die vollen Daten zu X-072 (" Follow-up data from Part A and Part B of the PROCLAIM-072 trial is expected to be presented in October at the Annual Meeting of the European Society of Medical Oncology in Munich, Germany.")
CytomX Therapeutics Announces Second Quarter 2018 Financial Results
Wed August 8, 2018 4:04 PM|GlobeNewswire|About: CTMX
Q2: 08-02-18 Earnings Summary
10-Q
News
EPS of $-0.35 misses by $-0.03
Revenue of $21.34M (+ 143.9% Y/Y) beats by $2.12M
- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) -
- Preliminary Proof-of-Concept for Probody™ Platform and CX-072 -
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today reported second quarter 2018 financial results.
As of June 30, 2018, CytomX had cash, cash equivalents and short-term investments of $335.1 million.
“The highlight of our second quarter was the presentation of encouraging data from our first clinical trial of CX-072, a PD-L1-targeting Probody therapeutic, comprising a critical milestone for the Company,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics (CTMX). “Based on these promising initial clinical findings, we have broadened the CX-072 development program to encompass eight distinct tumor types as we explore the full potential of this molecule, while continuing to advance combination arms with Yervoy® and Zelboraf®. We also continued to make progress across our entire therapeutic pipeline including the entry of our fourth program into the clinic, CX-2029, a CD71 Probody drug conjugate, in collaboration with AbbVie. The CytomX team continues to execute at a high level as we drive towards realizing our company vision of transforming patients’ lives.”
Business Highlights and Recent Developments
PROCLAIM-CX-072 (PD-L1 Probody Therapeutic) Clinical Program
CX-072 is a Probody therapeutic targeting PD-L1, a clinically- and commercially-validated anti-cancer target.
CytomX presented preliminary clinical data with an April 20, 2018 data cutoff from two arms of the Phase 1/2 PROCLAIM-CX-072 program at the 2018 ASCO Annual Meeting.
CX-072 monotherapy dose escalation arm evaluating CX-072 in patients with advanced unresectable solid tumors or lymphomas (Part A)
CX-072 was generally well tolerated in the 22 patients treated, Grade 3/4 TRAEs were reported in two patients with both events successfully managed with therapeutic intervention including steroids and discontinuation of CX-072 with the maximum tolerated dose (MTD) not reached.
CX-072 demonstrated encouraging efficacy in the 20 evaluable patients with objective responses in 3 (15%) patients, all occurring at doses of 3mg/kg or above. Stable disease was observed in 8 (40%) patients.
CX-072 in combination with Yervoy® (ipilimumab) in patients with advanced unresectable solid tumors or lymphomas (Part B)
CX-072 in combination with ipilimumab was generally well tolerated in the 16 patients treated with five (31%) reporting a Grade 3/4 TRAE with the MTD not reached at the time of data cutoff.
CX-072 in combination with ipilimumab demonstrated encouraging efficacy in the 12 evaluable patients with objective responses in 3 (25%) patients and stable disease observed in 8% of the patients, for an overall Disease Control Rate of 33%.
CytomX also presented a preliminary single-dose pharmacokinetic analysis showing that CX-072 as a single-agent, as designed, circulates predominantly as the intact masked prodrug across all dose levels.
Based on encouraging data from the PROCLAIM-CX-072 monotherapy arm, CytomX announced the opening of expansion cohorts in 8 undisclosed tumor types at the dose of 10mg/kg (Part D).
Follow-up data from Part A and Part B of the PROCLAIM-072 trial is expected to be presented in October at the Annual Meeting of the European Society of Medical Oncology in Munich, Germany.
CytomX expects to present initial data from the accompanying CX-072 translational science program in the second half of 2018.
PROCLAIM-CX-2009 (CD166 Probody Drug Conjugate) Clinical Program
CX-2009 is a Probody drug conjugate (PDC) that targets CD166, an antigen that is broadly and highly expressed in many types of cancer.
Dose escalation continues in Part A of the PROCLAIM-CX-2009 Phase 1/2 clinical program and preliminary data is expected to be presented in the second half of 2018.
CX-2029 (CD71 Probody Drug Conjugate) Clinical Program
CytomX, in collaboration with AbbVie, is advancing CX-2029, a CD71-directed PDC.
Clearance of the Investigational New Drug (IND) application for CX-2029 was received from the U.S. Food and Drug Administration in May 2018.
The first subject enrolled in the PROCLAIM-CX-2029 Phase 1/2 dose escalation trial has been treated.
CX-188 (PD-1 Probody Therapeutic) Preclinical Program
CytomX is advancing CX-188, a PD-1-directed Probody therapeutic, through IND-enabling studies.
CytomX expects to file an IND application for CX-188 in the second half of 2018.
Corporate Highlights
In July, CytomX completed an underwritten public offering of 5,867,347 shares of its common stock at a price of $24.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 765,306 additional shares of common stock. The public offering resulted in net proceeds of $134.5 million to CytomX. Proceeds from the offering are not reflected in the Company's June 30, 2018 balance sheet.
CytomX announced the appointment of Lloyd A. Rowland, Jr. as Senior Vice President, General Counsel.
Second Quarter 2018 Financial Results
Cash, cash equivalents and short-term investments totaled $335.1 million as of June 30, 2018, compared to $374.1 million as of December 31, 2017.
Revenue was $21.3 million for the three months ended June 30, 2018, compared to $8.8 million for the three months ended June 30, 2017. The increase was primarily attributable to the recognition of $9.9 million in revenue of the $21 million (net of the associated sublicense fee of $4 million) milestone payment from AbbVie related to the clearance of the CX-2029 IND, an increase of $1.6 million in revenue related to the Amgen collaboration, an increase of $1.4 million in revenue related to the BMS collaboration, and an increase of $0.7 million in revenue from the collaboration extension agreement with ImmunoGen, partially offset by a decrease in revenue of $0.5 million from the termination of the Pfizer collaboration in March 2018.
Research and development expenses decreased by $2.5 million during the three months ended June 30, 2018 compared to the corresponding period in 2017. The net decrease was primarily attributed to a $10.0 million sublicense payment to UCSB in Q2 2017, which was triggered by the $200 million upfront payment from BMS, offset by a $4.6 million increase in lab contracts and services and clinical trial expenses related to CX-072 and CX-2009 into phase 1 / 2 clinical development, an increase of $2.5 million in personnel related expenses due to an increase in headcount and a $0.4 million sublicense fee payable to UCSB for the IND success criteria achieved on the AbbVie CD71 Agreement in Q2 2018.
General and administrative expenses increased by $3.0 million during the three months ended June 30, 2018 compared to the corresponding period in 2017. This increase was largely attributed to an increase of $1.4 million in personnel related expenses due to increases in headcount, an increase of $1.0 million in consulting expenses and an increase of $0.5 million in legal fees.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072), a PD-1-targeting Probody therapeutic wholly owned by CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029) are among cancer targets that have been considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. CytomX and its partners have four programs in the clinic. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy of CytomX’s or any of its collaborative partners’ product candidates, administered separately or in combination, CytomX’s ability and the ability of its collaborative partners to develop and advance product candidates into and successfully complete clinical trials, including CytomX’s Phase 1/2 clinical trials of CX-072, CX-2009 and CX-2029, the timing of any future clinical trials to be initiated by CytomX or any of its collaborative partners, CytomX’s expectations regarding the availability of clinical data, CytomX’s expectations with respect to its collaborations, and CytomX’s expectations regarding the timing of potential regulatory filings. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: three of CytomX’s product candidates under its Probody platform are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; CytomX’s dependence on the success of CX-072, CX-2009 and CX-2029; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in the United States and foreign countries. Projected net cash utilization and capital resources are subject to substantial risk of variance based on a wide variety of factors that can be difficult to predict. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2018. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Wed August 8, 2018 4:04 PM|GlobeNewswire|About: CTMX
Q2: 08-02-18 Earnings Summary
10-Q
News
EPS of $-0.35 misses by $-0.03
Revenue of $21.34M (+ 143.9% Y/Y) beats by $2.12M
- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) -
- Preliminary Proof-of-Concept for Probody™ Platform and CX-072 -
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today reported second quarter 2018 financial results.
As of June 30, 2018, CytomX had cash, cash equivalents and short-term investments of $335.1 million.
“The highlight of our second quarter was the presentation of encouraging data from our first clinical trial of CX-072, a PD-L1-targeting Probody therapeutic, comprising a critical milestone for the Company,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics (CTMX). “Based on these promising initial clinical findings, we have broadened the CX-072 development program to encompass eight distinct tumor types as we explore the full potential of this molecule, while continuing to advance combination arms with Yervoy® and Zelboraf®. We also continued to make progress across our entire therapeutic pipeline including the entry of our fourth program into the clinic, CX-2029, a CD71 Probody drug conjugate, in collaboration with AbbVie. The CytomX team continues to execute at a high level as we drive towards realizing our company vision of transforming patients’ lives.”
Business Highlights and Recent Developments
PROCLAIM-CX-072 (PD-L1 Probody Therapeutic) Clinical Program
CX-072 is a Probody therapeutic targeting PD-L1, a clinically- and commercially-validated anti-cancer target.
CytomX presented preliminary clinical data with an April 20, 2018 data cutoff from two arms of the Phase 1/2 PROCLAIM-CX-072 program at the 2018 ASCO Annual Meeting.
CX-072 monotherapy dose escalation arm evaluating CX-072 in patients with advanced unresectable solid tumors or lymphomas (Part A)
CX-072 was generally well tolerated in the 22 patients treated, Grade 3/4 TRAEs were reported in two patients with both events successfully managed with therapeutic intervention including steroids and discontinuation of CX-072 with the maximum tolerated dose (MTD) not reached.
CX-072 demonstrated encouraging efficacy in the 20 evaluable patients with objective responses in 3 (15%) patients, all occurring at doses of 3mg/kg or above. Stable disease was observed in 8 (40%) patients.
CX-072 in combination with Yervoy® (ipilimumab) in patients with advanced unresectable solid tumors or lymphomas (Part B)
CX-072 in combination with ipilimumab was generally well tolerated in the 16 patients treated with five (31%) reporting a Grade 3/4 TRAE with the MTD not reached at the time of data cutoff.
CX-072 in combination with ipilimumab demonstrated encouraging efficacy in the 12 evaluable patients with objective responses in 3 (25%) patients and stable disease observed in 8% of the patients, for an overall Disease Control Rate of 33%.
CytomX also presented a preliminary single-dose pharmacokinetic analysis showing that CX-072 as a single-agent, as designed, circulates predominantly as the intact masked prodrug across all dose levels.
Based on encouraging data from the PROCLAIM-CX-072 monotherapy arm, CytomX announced the opening of expansion cohorts in 8 undisclosed tumor types at the dose of 10mg/kg (Part D).
Follow-up data from Part A and Part B of the PROCLAIM-072 trial is expected to be presented in October at the Annual Meeting of the European Society of Medical Oncology in Munich, Germany.
CytomX expects to present initial data from the accompanying CX-072 translational science program in the second half of 2018.
PROCLAIM-CX-2009 (CD166 Probody Drug Conjugate) Clinical Program
CX-2009 is a Probody drug conjugate (PDC) that targets CD166, an antigen that is broadly and highly expressed in many types of cancer.
Dose escalation continues in Part A of the PROCLAIM-CX-2009 Phase 1/2 clinical program and preliminary data is expected to be presented in the second half of 2018.
CX-2029 (CD71 Probody Drug Conjugate) Clinical Program
CytomX, in collaboration with AbbVie, is advancing CX-2029, a CD71-directed PDC.
Clearance of the Investigational New Drug (IND) application for CX-2029 was received from the U.S. Food and Drug Administration in May 2018.
The first subject enrolled in the PROCLAIM-CX-2029 Phase 1/2 dose escalation trial has been treated.
CX-188 (PD-1 Probody Therapeutic) Preclinical Program
CytomX is advancing CX-188, a PD-1-directed Probody therapeutic, through IND-enabling studies.
CytomX expects to file an IND application for CX-188 in the second half of 2018.
Corporate Highlights
In July, CytomX completed an underwritten public offering of 5,867,347 shares of its common stock at a price of $24.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 765,306 additional shares of common stock. The public offering resulted in net proceeds of $134.5 million to CytomX. Proceeds from the offering are not reflected in the Company's June 30, 2018 balance sheet.
CytomX announced the appointment of Lloyd A. Rowland, Jr. as Senior Vice President, General Counsel.
Second Quarter 2018 Financial Results
Cash, cash equivalents and short-term investments totaled $335.1 million as of June 30, 2018, compared to $374.1 million as of December 31, 2017.
Revenue was $21.3 million for the three months ended June 30, 2018, compared to $8.8 million for the three months ended June 30, 2017. The increase was primarily attributable to the recognition of $9.9 million in revenue of the $21 million (net of the associated sublicense fee of $4 million) milestone payment from AbbVie related to the clearance of the CX-2029 IND, an increase of $1.6 million in revenue related to the Amgen collaboration, an increase of $1.4 million in revenue related to the BMS collaboration, and an increase of $0.7 million in revenue from the collaboration extension agreement with ImmunoGen, partially offset by a decrease in revenue of $0.5 million from the termination of the Pfizer collaboration in March 2018.
Research and development expenses decreased by $2.5 million during the three months ended June 30, 2018 compared to the corresponding period in 2017. The net decrease was primarily attributed to a $10.0 million sublicense payment to UCSB in Q2 2017, which was triggered by the $200 million upfront payment from BMS, offset by a $4.6 million increase in lab contracts and services and clinical trial expenses related to CX-072 and CX-2009 into phase 1 / 2 clinical development, an increase of $2.5 million in personnel related expenses due to an increase in headcount and a $0.4 million sublicense fee payable to UCSB for the IND success criteria achieved on the AbbVie CD71 Agreement in Q2 2018.
General and administrative expenses increased by $3.0 million during the three months ended June 30, 2018 compared to the corresponding period in 2017. This increase was largely attributed to an increase of $1.4 million in personnel related expenses due to increases in headcount, an increase of $1.0 million in consulting expenses and an increase of $0.5 million in legal fees.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072), a PD-1-targeting Probody therapeutic wholly owned by CytomX (CX-188) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029) are among cancer targets that have been considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. CytomX and its partners have four programs in the clinic. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy of CytomX’s or any of its collaborative partners’ product candidates, administered separately or in combination, CytomX’s ability and the ability of its collaborative partners to develop and advance product candidates into and successfully complete clinical trials, including CytomX’s Phase 1/2 clinical trials of CX-072, CX-2009 and CX-2029, the timing of any future clinical trials to be initiated by CytomX or any of its collaborative partners, CytomX’s expectations regarding the availability of clinical data, CytomX’s expectations with respect to its collaborations, and CytomX’s expectations regarding the timing of potential regulatory filings. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: three of CytomX’s product candidates under its Probody platform are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; CytomX’s dependence on the success of CX-072, CX-2009 and CX-2029; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in the United States and foreign countries. Projected net cash utilization and capital resources are subject to substantial risk of variance based on a wide variety of factors that can be difficult to predict. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2018. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Trading Spotlight
Antwort auf Beitrag Nr.: 58.313.288 von Rastelly am 26.07.18 22:02:30
http://www.4-traders.com/CYTOMX-THERAPEUTICS-INC-24239932/ne…
jetzt wird die 100 Tage Linie in Angriff genommen,
gestern ein Tagesplus mit 5 %, nachhaltig?
Die Zeit wird es zeigen oder die Ergebnisse am im August.
Gruss RS
Cytomx
plant, Finanzergebnisse des zweiten Quartals 2018 am Mittwoch, den 8. August 2018, nach dem Ende der US-Märkte zu berichten.http://www.4-traders.com/CYTOMX-THERAPEUTICS-INC-24239932/ne…
jetzt wird die 100 Tage Linie in Angriff genommen,
gestern ein Tagesplus mit 5 %, nachhaltig?
Die Zeit wird es zeigen oder die Ergebnisse am im August.
Gruss RS
Paar Updates:
- zur ESMO 2018 gibt es 2 Poster zu CX-072, einmal Mono und einmal Kombi mit Ipilimumab
- BMS-986249 hat jetzt 8 Kliniken auf rekrutierend
- CX-2029 hat jetzt 3 Kliniken auf rekrutierend
- zur ESMO 2018 gibt es 2 Poster zu CX-072, einmal Mono und einmal Kombi mit Ipilimumab
- BMS-986249 hat jetzt 8 Kliniken auf rekrutierend
- CX-2029 hat jetzt 3 Kliniken auf rekrutierend
Nach Abschluss des Verkaufs am 17.07.2018 von 5.102.041 Stammaktien zu einem Preis von 24,50 $ verblieben CytomX116,9 Millionen US-Dollar, nach Abzug von Emissionsrabatten und Provisionen sowie geschätzten Angebotskosten.
Darüber hinaus hat CytomX den Zeichnern des Angebots eine 30-tägige Option zum Kauf von bis zu 765.306 weiteren Stammaktien zum öffentlichen Ausgabepreis gewährt, abzüglich der Zeichnungsabschläge und Provisionen.
Jedenfalls kommt wieder Bewegung in den Aktienkurs und die Aktie tendiert heute die 200 Tage Linie von unten,
Gruss RS
Darüber hinaus hat CytomX den Zeichnern des Angebots eine 30-tägige Option zum Kauf von bis zu 765.306 weiteren Stammaktien zum öffentlichen Ausgabepreis gewährt, abzüglich der Zeichnungsabschläge und Provisionen.
Jedenfalls kommt wieder Bewegung in den Aktienkurs und die Aktie tendiert heute die 200 Tage Linie von unten,
Gruss RS
Mal kurz das, was mir zu der Kapitalerhöhung im Kopf rumschwirrt:
- Wenn sie wirklich die Eigenentwicklungen massiv voran treiben wollen, dann ist der bestehende Cash schnell weg. Allerdings sehe ich das so in der Pipeline noch nicht und der aktuelle Cash Burn gibt diese Einschätzung nicht her.
- Vielleicht fürchten sie auch einen Börsencrash und wollen vorsorgen?
- Bei der massiven Anzahl Stock Options für die Leitung und die Mitarbeiter müssten sie schon ein Interesse haben, keine unnötige Verwässerung zu betreiben.
- Vielleicht wollen unauffällig neue Ankeraktionäre einsteigen?
Das wahrscheinlichste ist wohl wirklich, dass Cytomx bei den Eigenentwicklungen und in der Forschung künftig Vollgas geben will.
Was ich nicht verstehe sind die 9% Kursverlust, nachdem die erfolgreiche KE abgeschlossen ist. Aber solche Sprünge hatten wir schon öfters...
- Wenn sie wirklich die Eigenentwicklungen massiv voran treiben wollen, dann ist der bestehende Cash schnell weg. Allerdings sehe ich das so in der Pipeline noch nicht und der aktuelle Cash Burn gibt diese Einschätzung nicht her.
- Vielleicht fürchten sie auch einen Börsencrash und wollen vorsorgen?
- Bei der massiven Anzahl Stock Options für die Leitung und die Mitarbeiter müssten sie schon ein Interesse haben, keine unnötige Verwässerung zu betreiben.
- Vielleicht wollen unauffällig neue Ankeraktionäre einsteigen?
Das wahrscheinlichste ist wohl wirklich, dass Cytomx bei den Eigenentwicklungen und in der Forschung künftig Vollgas geben will.
Was ich nicht verstehe sind die 9% Kursverlust, nachdem die erfolgreiche KE abgeschlossen ist. Aber solche Sprünge hatten wir schon öfters...
den grund werden wir vermutlich nicht erfahren. was ist schlecht an einem dicken cashpolster?
Durchsuchen
CytomX - ein bahnbrechender Ansatz in der Tumortherapie
